GlassScriptPhysician profile
Faiza Khan
NPI 1417515800
$4,238.50
in general payments reported to CMS, 2019-2025
36 companies · $765 in 2025
The $765 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $754 · 2022: $1,121 · 2023: $890 · 2024: $709 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $383.80 | 2021-2024 | Minimed 780g, Accurian |
| Abbott Laboratories | $288.59 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $251.53 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $244.91 | 2021-2025 | Jardiance, Mounjaro, Lyumjev |
| Abbvie INC. | $230.34 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $205.57 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.82 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $163.52 | 2021-2025 | Evenity, Prolia, Prolia |
| Recordati_rare_diseases_inc. | $123.25 | 2021-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $116.84 | 2022-2023 | Afrezza |
| Amneal Pharmaceuticals LLC | $109.82 | 2022-2025 | Unithroid |
| Corcept Therapeutics | $107.67 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $101.29 | 2021-2022 | |
| Becton, Dickinson and Company | $99.18 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $84.99 | 2022-2023 | Senza |
| Halozyme INC | $78.78 | 2023 | |
| Antares Pharma, INC. | $65.98 | 2022-2024 | Xyosted, Tlando |
| Ibsa Pharma INC. | $63.75 | 2021-2025 | Tirosint, Flector, Licart |
| Amryt Pharma Holdings LTD | $55.57 | 2022-2023 | Mycapssa |
| Dexcom, INC. | $38.78 | 2024 | Dexcom G6 Transmitter |
| Clarus Therapeutics INC. | $36.16 | 2021 | |
| Embecta Corp. | $35.44 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amarin Pharma, INC. | $30.73 | 2021 | |
| Eusa Pharma (US) LLC | $26.41 | 2022 | |
| Insulet Corporation | $26.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.81 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.23 | 2021 | |
| Madrigal Pharmaceuticals | $19.94 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $19.20 | 2025 | Twiist |
| Verity Pharmaceuticals INC. | $19.07 | 2025 | Tlando |
| Acella Pharmaceuticals, LLC | $18.05 | 2025 | NP Thyroid 60 |
| Alvogen INC | $18.02 | 2024 | Teriparatide |
| Neurocrine Biosciences, INC. | $17.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.62 | 2022 | |
| Lifescan, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.